Formulation Development
ARTIFICIAL INTELLIGENCE - The AI-Driven Path to Precision Therapeutics
Rotem Gura-Sadovsky, PhD, and Maayan Eilon-Ashkenazy, PhD, explore the potential for AI to transform drug discovery, charting a path towards more targeted precision therapeutics.
BIOAVAILABILITY & SOLUBILITY - Formulation Strategies for Tackling Poor Oral Bioavailability
Richard Johnson, PhD, says better characterization of NCEs in the early stages of development and identifying solubility issues early offers the opportunity to address poor bioavailability using formulation techniques that deliver enhanced drug exposure – reducing risk, conserving resources, and increasing the chances of clinical success.
Piramal Pharma Solutions & Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development & Manufacturing
Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services have announced a strategic collaboration. Under this collaboration, Piramal will refer applicable customers seeking ADC manufacturing technology to…
CML ADVANCES - To Improve Upon a Miracle Drug: Overcoming Drug Resistance & Intolerance in CML
Ben Hohl, says while imatinib and other TKIs have undoubtedly positively impacted the lives of many people living with CML, thousands of patients are still looking for drugs that provide better efficacy, tolerability, and convenience.
EXECUTIVE INVTERVIEW - Klotho Neurosciences: Focused on Neurodegenerative & Age-Related Disorders
Dr. Joseph Sinkule, Founder & CEO of Klotho Neurosciences, discusses the company, its therapies, the human Klotho gene, and longevity.
Ardena Opens New Bioanalytical Laboratory in New Jersey
Ardena recently announced its new state-of –the-art GLP bioanalytical laboratory in Somerset, New Jersey, is now operational and supporting client studies. The 2,500+ sqft laboratory…
First Patients Dosed With Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle Platform
Cellares recently announced that Cabaletta Bio Inc.’s investigational CAR T cell therapy rese-cel (resecabtagene autoleucel) has been infused into the first two patients using drug…
POLYMACROCYCLIC PEPTIDES - Engineering Structure for Function in Next Generation Therapeutics
Karsten Eastman, PhD, and Vahe Bandarian, PhD, believe the key challenge, and opportunity, is to sculpt peptide architecture so that shape and chemistry are presented to the target in the right place, at the right time, and for long enough to matter clinically.
TECHNOLOGY TRANSFER - Streamlining Biologics Technology Transfer Through Integrated Operational Models
Lalit Saxena explains how technology transfer in biologics manufacturing is an inherently complex process that requires the simultaneous control of multiple scientific, technical, and operational variables.
THERAPEUTIC FOCUS - Advancing Adjunctive Therapies for Depression & OCD Using Translational Pharmaceutics®
Jacob Jacobsen, PhD, Bret Berner, PhD, and Vanessa Zann, PhD, review a partnership with Evecxia Therapeutics to support the development of EVX-101, an investigational adjunctive drug for depression and obsessive-compulsive disorder (OCD) responding inadequately to first-line antidepressants.
RADIOLIGAND THERAPIES - Affibody Molecules: A Versatile Approach to Radiopharma
Fredrik Frejd reviews Affibody’s lead RLT candidate, ABY-271, currently being evaluated in a first-in-human clinical study in HER2 positive metastatic breast cancer.
Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head & Neck Cancer
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced the completion of patient randomization…
PannTheraPi Announces Significant Clinical Development & Strategic Milestones
PannTheraPi recently announced significant progress in its clinical development alongside a key leadership appointment to strengthen its scientific and operational capabilities. The company has submitted…
ProImmune Collaborates With The University of Texas Medical Branch to Advance Infectious Disease Research
ProImmune, Ltd.recently announced a collaboration with The University of Texas Medical Branch (UTMB) Galveston National Laboratory (GNL), a high-containment, infectious disease research facility, to develop…
Symbiosis Expands Commercial Capabilities With Addition of New Stability Chamber
Symbiosis Pharmaceutical Services has expanded its Quality Control (QC) laboratory with the installation of a new 30°C stability chamber. This addition enables Symbiosis to replicate…
Alzheon Advances Next-Gen Pipeline With First Patient Dosed in ALZ-507 Study
Alzheon, Inc. recently announced the dosing of the first cohort of human volunteer subjects in a Phase 1 single and multiple ascending dose clinical trial of…
Cereno Scientific Reports Robust Safety & Tolerability in Long‑Term CS1 Pulmonary Arterial Hypertension Study
Cereno Scientific provides additional context on the safety and tolerability data from up to 12 months of treatment from the Expanded Access Program (EAP) with…
ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology
ANI Pharmaceuticals, Inc. recently announced publication of the results from the NEW DAY clinical trial involving ILUVIEN (fluocinolone acetonide intravitreal implant), 0.19 mg (ILUVIEN) for…
FORE Biotherapeutics Receives Breakthrough Therapy Designation for Plixorafenib
FORE Biotherapeutics, a registration-stage company dedicated to developing targeted therapies to treat patients with cancer, today announced that the U.S. Food and Drug Administration (FDA)…
Adragos Pharma Finalizes the Acquisition of Commercial-Scale, Sterile Fill-Finish Manufacturing Site From Sanofi
Adragos Pharma recently announced it completed the acquisition of a commercial-scale sterile fill-finish facility in Maisons-Alfort, France, from Sanofi. The Maisons-Alfort site is one of…
